Vertex Pharmaceuticals
We're hiring — explore open roles below and apply in a few clicks.
Location
Headquarters: Boston, Massachusetts, United States, North America
Region: Massachusetts
Country: US
Continent: North America
About
Vertex is a global biopharmaceutical company focused on discovering, developing, and commercializing transformative medicines for people with serious diseases. The company emphasizes scientific innovation across its research and development efforts, with a geographically diverse footprint including the United States and global operations. Its portfolio includes therapies for conditions such as cystic fibrosis and other serious illnesses, underscoring a commitment to advancing patient care through biology-driven medicine.
Vertex Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes transformative medicines for serious diseases. Its primary focus is on treating cystic fibrosis and other genetic disorders through biology-driven research. Key products include Kalydeco, Orkambi, Symdeko, and Trikafta, which target specific genetic mutations to improve patient outcomes.
Vertex Pharmaceuticals, Inc
1989
for_profit
active
Industries
Primary Industry: Business Services
Categories
Funding & Financials
post_ipo_secondary
848900000
over-1b
ipo
NASDAQ:VRTX
nasdaq
Investors
Founders
Joshua Boger
Kevin Kinsella
Larry Bock
Leadership
Reshma Kewalramani — President and Chief Executive Officer
Jeffrey Leiden — Executive Chairman
Nina Devlin — Senior Vice President and Chief Communications Officer
Ludovic Fenaux — Senior Vice President, International Commercial Operations
Megan Krench — Director of BD - External Innovation
John Gray — Senior Vice President, Genetic Therapies Research
Fabio Zuccotto — Director Computational Drug Design
David Altshuler — Executive Vice President, Global Research and Chief Scientific Officer
Technology Stack
Products
KALYDECO® (ivacaftor): An oral medication for treating cystic fibrosis by targeting specific genetic mutations to improve lung function.
ORKAMBI® (lumacaftor/ivacaftor): A combination oral therapy for cystic fibrosis that targets the defective CFTR protein to improve lung function in patients with specific mutations.
SYMDEKO® (tezacaftor/ivacaftor and ivacaftor): An oral combination therapy for cystic fibrosis that improves CFTR protein function in patients with specific mutations.
TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor): An oral triple combination therapy for cystic fibrosis that targets multiple defects in the CFTR protein to improve lung function in patients with specific mutations.
ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor): An oral combination therapy for cystic fibrosis aimed at improving CFTR protein function in patients with certain mutations.
CASGEVY® (exagamglogene autotemcel): A gene therapy administered via intravenous infusion for treating certain genetic diseases by modifying patient cells.
Funding rounds
Post Ipo Secondary · $1.11M · (2024-07-10)
Post Ipo Equity · $50M · (2022-05-17)
Post Ipo Equity · $443M · (2009-12-03)
Connect
Connect
Open positions(14)
- Senior Software Engineer - DevOps / Infrastructure (Onsite)Full-timeWork from OfficeUS-VA-STERLING-291 ~ 22640 Davis Dr ~ DAVIS95,500–181,700 / Year
- Lead Engineer – DevOps (4–6 Years of Experience)Full-timeHybridIN-TS-HYDERABAD-B3F7 ~ DLF Cybercity Gachibowli ~ DLF CYBERCITY GACHIBOWLI-B3F7, 7th Fl in Block 3
- Sr. Engineer - DevOps (Remote)Full-timeWork from HomeUS-NC-REMOTE107,500–204,500 / Year
- Senior Full Stack EngineerFull-timeWork from HomeUS-CT-REMOTE132,400–251,600 / Year
- SAP BTP Integration Suite Developer (Remote)Full-timeWork from HomeUS-NC-REMOTE107,500–204,500 / Year
- SAP BTP Integration Suite Developer (Remote)PremiumFull-timeWork from HomeUS-NC-REMOTE68,900–131,100 / Year
- SAP DeveloperFull-timeHybridHarlow, Essex
- Automation DeveloperFull-timeHybridIN-KA-BENGALURU-NORTHGATE ~ Sy No 2/2 Venkatala Village ~ SY NO 2/2 VENKATALA VILLAGE, Yelahanka Hobli
- Principal Data Scientist – Factory IntelligencePremiumFull-timeHybridUS-AZ-TUCSON-M09 ~ 3350 E Hemisphere Loop ~ BLDG M09107,500–204,500 / Year
- Immunology Senior Research Scientist - Spatial TranscriptomicsPremiumFull-timeWork from OfficeSeattle, WA124,200–186,400 / Year
- Immunology Senior Research Scientist - Flow CytometryFull-timeWork from OfficeSeattle, WA124,200–186,400 / Year
- Research Scientist - Autonomous Collaborative SystemsPremiumFull-timeHybridUS-CT-EAST HARTFORD-RTRC K ~ 411 Silver Ln ~ RTRC K107,500–204,500 / Year
- Maintenance Forecasting AnalystPremiumFull-timeHybridUS-CT-EAST HARTFORD-ETC ~ 400 Main St ~ BLDG ETC86,800–165,200 / Year
- Principal Engineer, AI AuthoringFull-timeHybridBoston, MA166,640–250,000 / Year